Crinetics Pharmaceuticals, Inc. (CRNX) is a publicly traded Healthcare sector company. As of May 21, 2026, CRNX trades at $36.28 with a market cap of $3.66B and a P/E ratio of -7.30. CRNX moved +3.84% today. Year to date, CRNX is -24.72%; over the trailing twelve months it is +15.62%. Its 52-week range spans $24.10 to $62.53. Analyst consensus is strong buy with an average price target of $86.00. Rallies surfaces CRNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Crinetics Launches Palsonfi with 50% QuickStart Patients, Maintains $1B Cash Runway: Crinetics defined normalization of urinary cortisol as the primary endpoint for its Palsonfi phase 2/3 study, enabling measurement of biochemical markers alongside clinical outcomes like glucose and blood pressure improvements. The company has 50% of patients on QuickStart, 200 Q4 enrollments and over $1 billion cash supporting operations into 2030.
| Metric | Value |
|---|---|
| Price | $36.28 |
| Market Cap | $3.66B |
| P/E Ratio | -7.30 |
| EPS | $-4.95 |
| Dividend Yield | 0.00% |
| 52-Week High | $62.53 |
| 52-Week Low | $24.10 |
| Volume | 581.00K |
| Avg Volume | 0 |
| Revenue (TTM) | $7.70M |
| Net Income | $-465.32M |
| Gross Margin | 86.02% |
10 analysts cover CRNX: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $86.00.